Long-Term Control
At the HOME VII meeting, two instruments were recommended for the COS:
Note: The ADCT and RECAP were both developed in response to a call at HOME V in 2017 for instruments to be developed to measure eczema control. These instruments and their validation studies will be published in due course and made available via the HOME website.
ADCT and Recap are very similar instruments, and are both newly developed and showed good measurement properties on initial testing. However, it was not possible to select between them until more information is available on how they both perform in trials. Therefore, either can be used for the COS for the time being.
Further validation studies are required, including cross-cultural validation studies and translations, as well as studies to investigate how well a single-item control question performs. If you are interested in carrying out any of this work, please contact home@nottingham.ac.uk.
Related publications
Validation of the RECAP measure of eczema control for use in dermatology clinics
Bhanot A, Vincent R, Peters TJ, Ridd MJ
Clin Exp Dermatol. 2021 Sep 15. doi: 10.1111/ced.14934. Online ahead of print (Abstract Link)
Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP)
Howells L, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, Howie L, Lawton S, Ridd M, Rogers NK, Sears AV, Spuls P, von Kobyletzki L, Thomas KS.
Br J Dermatol. 2019 Dec 3. doi: 10.1111/bjd.18780. [Epub ahead of print] (Abstract Link)
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, Nelson L, Mahajan P, Reaney M, Guillemin I, Mallya UG, Eckert L.
Curr Med Res Opin. 2019 Dec 12:1-10. doi: 10.1080/03007995.2019. 1699516 [Epub ahead of print] (Abstract link)
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D.
BMC Dermatol. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3 (Abstract Link)
Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review
Barbarot S, Rogers NK, Abuabara K, Aubert H, Chalmers J, Flohr C, Hanifin J, Naldi L, Margolis DJ, Paul C, Ridd MJ, Anna Schuttelaar ML, Simpson E, Tauber M, Volke A, Weidinger S, Wilkes SR, Wollenberg A, Thomas KS.
J Am Acad Dermatol 2016 Nov; 75(5):1038-1044. doi: 10.1016\jaad.2016.05.043 (Abstract Link)
Validation of treatment escalation as a definition of atopic eczema flares.
Thomas KS, Stuart B, O'Leary CJ, Schmitt J, Paul C, Williams HC, Langan S.
PLoS One 2015 Apr 21;10(4):e0124770. doi: 10.1371/journal.pone.0124770. (Abstract Link)
How are eczema "flares" defined? A systematic review and recommendation for future studies
Langan SM, Schmitt J, Williams HC, Smith S, thomas KS.
Br J Dermatol 2014 Mar;170(3):548-56. doi: 10.1111/bjd.12747 (Abstract Link)